Dexamethasone chronotherapy of COVID-19 patients admitted to intensive care unit: an exploratory study
Open Access
- 27 August 2025
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-10
Abstract
Dexamethasone has been demonstrated to be a potential treatment approach preventing COVID-19 related fatalities by managing the cytokine release storm (CRS). The expression of the inflammatory mediators involved in the CRS is regulated by the circadian biology of the immune response and it peaks during the evening. Accordingly, it has been hypothesized that the administration of anti-inflammatory medications in the evening could help better manage the CRS. Therefore, we investigated the association between dexamethasone administration time and COVID-19 mortality. A retrospective cohort study was conducted using electronic health records of COVID-19 patients hospitalized in the State of Qatar between March 2020 and April 2021. The exposure group received dexamethasone between 16:00 h and 04:00 h, while the control group received dexamethasone between 04:00 h and 16:00 h. From the 875 COVID-19 patients included in the study, 161 received dexamethasone treatments between 16:00 h and 04:00 h while 714 received it between 04:00 h and 16:00 h. After adjusting for confounding variables, dexamethasone given between 16:00 h and 04:00 h was associated with lower odds of COVID-19 mortality (OR: 0.22, CI 95%: 0.06, 0.84). Dexamethasone administration tailored to the circadian rhythm was associated with lower odds of mortality in hospitalized COVID-19 patients.Keywords
Funding Information
- QNRF Rapid Response Grant (RRC02‐0810‐210032, RRC02‐0810‐210032, RRC02‐0810‐210032, RRC02‐0810‐210032)
This publication has 57 references indexed in Scilit:
- A Systematic Review of Systematic Reviews on the COVID-19 PandemicSN Comprehensive Clinical Medicine, 2021
- Systematic review and meta‐analysis of effectiveness of treatment options against SARS‐CoV‐2 infectionJournal of Medical Virology, 2020
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trialJournal of Allergy and Clinical Immunology, 2020
- Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventionsAutoimmunity Reviews, 2020
- Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19Journal of Medical Virology, 2020
- Sleep and Circadian Rhythm in Critical Illness2019
- Endogenous circadian regulation of pro-inflammatory cytokines and chemokines in the presence of bacterial lipopolysaccharide in humansBrain, Behavior, and Immunity, 2015
- The expression of cytokine activity by fracture callusJournal of Bone and Mineral Research, 1995
- Pharmacokinetics of dexamethasone and its phosphate esterBiopharmaceutics & Drug Disposition, 1987
- A comparison of the bioavailability and potency of dexamethasone phosphate and sulphate in manEuropean Journal of Clinical Pharmacology, 1981